Monday, 24 October 2016
Meeting category
Date(s)
24 Oct 2016
Location
Liverpool,
United Kingdom
Organizer
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Related Enduring Materials
Enduring Materials
Session 1: Pharmacokinetics & pharmacodynamics of new & redeveloped TB drugs -
chair
Rob Aarnoutse, PharmD, PhD
Radboud University Medical Center, The Netherlands
Abstract presentations
A model-based analysis to describe bedaquiline’s exposure-response relationship and predict the impact of drug-drug interactions
Population Pharmacokinetics of AZD5847 in Adults with Pulmonary Tuberculosis
Pharmacokinetic Modeling and Simulation of the Interaction between Moxifloxacin and Rifapentine in Healthy Volunteers
Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin
Pharmacokinetics & pharmacodynamics of existing TB drugs -
Chairs
Eric Nuermberger, MD
Johns Hopkins University, USA
Ulrika Simonsson, PharmD, PhD
Uppsala University, Sweden
Rifampin vs. Rifapentine: a debate over the preferred rifamycin
Abstract presentations
Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis
Early interventions for diabetes related tuberculosis hasten sputum microbiological clearance in Virginia, USA
Sub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation
A Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis
Session 3: Population pharmacokinetics and pharmacokinetic-pharmacodynamic modelling -
Chairs
Helen McIlleron, MBChB, PhD
University of Cape Town, South Africa
Russell Kempker, MD, MSc
Emory University School of Medicine, USA
Abstract presentations
Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis.
Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects
A translational modelling and simulations approach to exploit pre-clinical tuberculosis data
The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS
Session 4: Drug development and optimization: approaches and tools -
Chairs
Gerry Davies
University of Liverpool, United Kingdom
Paolo Denti, PhD
University of Cape Town, South Africa
Long acting (LA) drug delivery in TB treatment
Abstract presentations
Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling
High drug tolerance of Mycobacterium tuberculosis in caseum
Rifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection
Exploration of Non-Replicating Mycobacterium Tuberculosis In Vitro System Through Mathematical Modelling
Overview
Welcome
Dear colleagues,
The 9th edition of the International Workshop on Pharmacology of Tuberculosis Drugs, which has been organized 24 October 2016 in Liverpool, United Kingdom (prior to the Union Meeting) has been another very successful edition.
Excellent presentations were given by the invited speakers and a record amount of abstracts were presented as a poster or oral presentation.
We would like to thank all attendees for their participation and input and we would like to express our appreciation to everyone who took the time to fill in the evaluation form at the end of the conference. Thank you for your feedback and suggestions!
Kind regards,
The Organizing Committee
The Organizing Committee
Khisi Mdluli, PhD
TB Alliance, USA
General Information
Meeting Objectives
- To gather experts involved in the pharmacology of TB drugs from different disciplines in an interactive workshop setting
- To provide a platform for presentation and discussion of the latest scientific developments in the field.
- To map all current studies and results related to available and new TB drugs
- To help translate new in vitro and in vivo pharmacological data into new drug treatment combinations for TB
- To provide a platform for presentation and discussion of the latest scientific developments in the field.
- To map all current studies and results related to available and new TB drugs
- To help translate new in vitro and in vivo pharmacological data into new drug treatment combinations for TB
Unique Features
Our workshop involves a strong community of clinical pharmacologists and other healthcare professionals working in the TB-field. Also, the workshop provides an independent scientific platform to discuss controversial topics and views.
Practical Information
Language
The official conference language was English.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Expert Medical Events, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Expert Medical Events disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Photograph, Audio and Video Recording
Photographs as well as audio and video recordings are not permitted during official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted on the workshop website as soon as possible following the meeting, provided the speaker has given us permission to use their presentation online.
